PriceTargets.com logo

Axsome Therapeutics - AXSM Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $169.87
  • Forecasted Upside: 51.34%
  • Number of Analysts: 16
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 16 Buy Ratings
  • 0 Strong Buy Ratings
$112.24 As of 05/1/2025 05:00 PM ET
▼ -0.05 (-0.04%)

This chart shows the closing price for AXSM by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
MarApr$112.24Closing price on 05/01/25:
Get New Axsome Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AXSM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AXSM

Analyst Price Target is $169.87
▲ +51.34% Upside Potential
This price target is based on 16 analysts offering 12 month price targets for Axsome Therapeutics in the last 3 months. The average price target is $169.87, with a high forecast of $216.00 and a low forecast of $105.00. The average price target represents a 51.34% upside from the last price of $112.24.

This chart shows the closing price for AXSM for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart
4/247/2410/241/255/255/26$50$91$133$174$216Closing price on 05/01/25: $112.24High$216.00Average$169.87Low$105.00




Current Consensus is Buy

The current consensus among 16 contributing investment analysts is to buy stock in Axsome Therapeutics. This rating has held steady since August 2024, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 8 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
11/9/2023
  • 0 strong buy ratings
  • 9 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
2/7/2024
  • 0 strong buy ratings
  • 12 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/7/2024
  • 0 strong buy ratings
  • 13 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/5/2024
  • 0 strong buy ratings
  • 14 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/3/2024
  • 0 strong buy ratings
  • 14 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/1/2025
  • 0 strong buy ratings
  • 15 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/2/2025
  • 0 strong buy ratings
  • 16 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/2/2025

Latest Recommendations

  • 0 strong buy ratings
  • 16 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
4/29/2025Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$190.00 ➝ $193.00
4/7/2025Jefferies Financial GroupInitiated CoverageBuy ➝ Buy$200.00
4/3/2025HC WainwrightReiterated RatingBuy ➝ Buy$200.00 ➝ $200.00
4/1/2025Needham & Company LLCReiterated RatingBuy ➝ Buy$153.00 ➝ $153.00
3/27/2025MizuhoBoost TargetOutperform ➝ Outperform$212.00 ➝ $216.00
3/6/2025HC WainwrightReiterated RatingBuy ➝ Buy$200.00 ➝ $200.00
3/3/2025Needham & Company LLCReiterated RatingBuy ➝ Buy$153.00 ➝ $153.00
3/3/2025Robert W. BairdBoost TargetOutperform ➝ Outperform$132.00 ➝ $160.00
2/27/2025Morgan StanleyBoost TargetOverweight ➝ Overweight$125.00 ➝ $190.00
2/26/2025MizuhoBoost TargetOutperform ➝ Outperform$195.00 ➝ $212.00
2/20/2025HC WainwrightBoost TargetBuy ➝ Buy$190.00 ➝ $200.00
2/19/2025Truist FinancialBoost TargetBuy ➝ Buy$190.00 ➝ $200.00
2/19/2025Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$153.00 ➝ $153.00
2/19/2025Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$143.00 ➝ $192.00
2/19/2025Needham & Company LLCBoost TargetBuy ➝ Buy$133.00 ➝ $153.00
2/18/2025William BlairReiterated RatingOutperform
2/12/2025Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$140.00 ➝ $160.00
2/11/2025Bank of AmericaBoost TargetBuy ➝ Buy$143.00 ➝ $167.00
2/11/2025HC WainwrightReiterated RatingBuy ➝ Buy$190.00 ➝ $190.00
2/11/2025MizuhoBoost TargetOutperform ➝ Outperform$137.00 ➝ $195.00
2/11/2025Deutsche Bank AktiengesellschaftInitiated CoverageBuy$176.00
2/10/2025Leerink PartnersBoost TargetOutperform ➝ Outperform$110.00 ➝ $150.00
2/10/2025Needham & Company LLCReiterated RatingBuy ➝ Buy$133.00 ➝ $133.00
2/3/2025Robert W. BairdSet Target$132.00
2/3/2025MizuhoBoost TargetOutperform ➝ Outperform$122.00 ➝ $137.00
2/3/2025Truist FinancialBoost TargetBuy ➝ Buy$180.00 ➝ $190.00
1/31/2025HC WainwrightBoost TargetBuy ➝ Buy$180.00 ➝ $190.00
1/29/2025Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$139.00 ➝ $139.00
1/24/2025William BlairReiterated RatingOutperform
1/21/2025HC WainwrightReiterated RatingBuy ➝ Buy$180.00 ➝ $180.00
1/13/2025Needham & Company LLCReiterated RatingBuy ➝ Buy$133.00 ➝ $133.00
1/13/2025Truist FinancialBoost TargetBuy ➝ Buy$150.00 ➝ $180.00
1/6/2025Needham & Company LLCReiterated RatingBuy ➝ Buy$133.00 ➝ $133.00
12/31/2024MizuhoLower TargetOutperform ➝ Outperform$124.00 ➝ $122.00
12/31/2024HC WainwrightReiterated RatingBuy ➝ Buy
12/30/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$130.00 ➝ $130.00
12/12/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$121.00 ➝ $121.00
11/25/2024HC WainwrightReiterated RatingBuy ➝ Buy$180.00 ➝ $180.00
11/13/2024Robert W. BairdBoost TargetOutperform ➝ Outperform$112.00 ➝ $116.00
11/12/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$130.00 ➝ $130.00
10/4/2024Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$130.00 ➝ $131.00
9/16/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$107.00 ➝ $107.00
9/6/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$107.00 ➝ $107.00
9/5/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$130.00 ➝ $130.00
9/5/2024HC WainwrightReiterated RatingBuy ➝ Buy$180.00 ➝ $180.00
9/3/2024Wells Fargo & CompanyInitiated CoverageOverweight$140.00
8/22/2024HC WainwrightReiterated RatingBuy ➝ Buy$180.00 ➝ $180.00
8/6/2024UBS GroupLower TargetBuy ➝ Buy$107.00 ➝ $105.00
8/6/2024Royal Bank of CanadaLower TargetOutperform ➝ Outperform$131.00 ➝ $130.00
8/6/2024HC WainwrightLower TargetBuy ➝ Buy$190.00 ➝ $180.00
8/6/2024Bank of AmericaUpgradeNeutral ➝ Buy$95.00 ➝ $106.00
8/5/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$130.00 ➝ $130.00
7/26/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$107.00 ➝ $107.00
7/22/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$131.00 ➝ $131.00
7/22/2024Needham & Company LLCInitiated CoverageBuy$130.00
7/18/2024Bank of AmericaLower TargetNeutral ➝ Neutral$97.00 ➝ $95.00
6/12/2024MizuhoReiterated RatingBuy ➝ Buy$106.00 ➝ $106.00
6/6/2024HC WainwrightReiterated RatingBuy ➝ Buy$190.00 ➝ $190.00
6/5/2024Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$127.00 ➝ $130.00
5/8/2024MizuhoLower TargetBuy ➝ Buy$109.00 ➝ $106.00
5/7/2024CitigroupLower TargetBuy ➝ Buy$127.00 ➝ $125.00
5/7/2024HC WainwrightReiterated RatingBuy ➝ Buy$190.00
5/7/2024Robert W. BairdBoost TargetOutperform ➝ Outperform$108.00 ➝ $112.00
4/29/2024Morgan StanleyUpgradeEqual Weight ➝ Overweight$90.00 ➝ $115.00
4/10/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$107.00
4/2/2024HC WainwrightReiterated RatingBuy ➝ Buy$190.00
3/28/2024MizuhoBoost TargetBuy ➝ Buy$108.00 ➝ $109.00
3/26/2024Truist FinancialReiterated RatingBuy ➝ Buy$150.00
3/26/2024HC WainwrightBoost TargetBuy ➝ Buy$180.00 ➝ $190.00
3/26/2024CitigroupBoost TargetBuy ➝ Buy$125.00 ➝ $127.00
3/26/2024Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$123.00 ➝ $128.00
3/20/2024HC WainwrightReiterated RatingBuy ➝ Buy$180.00
3/19/2024Robert W. BairdInitiated CoverageOutperform$108.00
3/4/2024HC WainwrightReiterated RatingBuy ➝ Buy$180.00
2/27/2024MizuhoLower TargetBuy ➝ Buy$112.00 ➝ $108.00
2/21/2024GuggenheimBoost TargetBuy ➝ Buy$110.00 ➝ $125.00
2/21/2024Royal Bank of CanadaLower TargetOutperform ➝ Outperform$126.00 ➝ $123.00
2/20/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$108.00
2/16/2024MizuhoBoost TargetBuy ➝ Buy$90.00 ➝ $112.00
2/6/2024UBS GroupInitiated CoverageBuy$111.00
1/25/2024Royal Bank of CanadaInitiated CoverageOutperform$126.00
1/22/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$108.00
1/16/2024Piper SandlerBoost TargetOverweight ➝ Overweight$90.00 ➝ $113.00
12/26/2023HC WainwrightReiterated RatingBuy ➝ Buy$180.00
12/20/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$108.00
12/13/2023CitigroupInitiated CoverageBuy$125.00
12/12/2023HC WainwrightReiterated RatingBuy ➝ Buy$180.00
11/7/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$108.00
9/25/2023MizuhoReiterated RatingBuy ➝ Buy$100.00
8/28/2023MizuhoReiterated RatingBuy ➝ Buy$100.00
8/22/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$108.00
8/11/2023MizuhoBoost TargetBuy ➝ Buy$95.00 ➝ $100.00
8/8/2023HC WainwrightLower TargetBuy ➝ Buy$190.00 ➝ $180.00
8/8/2023Bank of AmericaUpgradeUnderperform ➝ Neutral$59.00 ➝ $81.00
8/7/2023Piper SandlerUpgradeNeutral ➝ Overweight$70.00 ➝ $90.00
8/7/2023William BlairReiterated RatingOutperform
7/17/2023HC WainwrightLower Target$200.00 ➝ $190.00
6/22/2023VNET GroupReiterated RatingReiterates
5/11/2023MizuhoBoost Target$84.00 ➝ $95.00
5/9/2023GuggenheimBoost Target$90.00 ➝ $100.00
5/9/2023Morgan StanleyBoost Target$83.00 ➝ $87.00
4/17/2023HC WainwrightReiterated RatingBuy$200.00
4/12/2023Morgan StanleyLower TargetEqual Weight$85.00 ➝ $83.00
3/20/2023HC WainwrightLower Target$210.00 ➝ $200.00
3/13/2023MizuhoReiterated RatingBuy$84.00
3/6/2023HC WainwrightReiterated RatingBuy$210.00
3/1/2023MizuhoLower TargetBuy$86.00 ➝ $84.00
2/28/2023GuggenheimLower TargetBuy$105.00 ➝ $90.00
2/28/2023Morgan StanleyLower TargetEqual Weight$86.00 ➝ $85.00
2/14/2023Bank of AmericaReiterated RatingUnderperform$52.00
2/14/2023HC WainwrightReiterated RatingBuy$210.00
1/30/2023MizuhoBoost TargetBuy$80.00 ➝ $86.00
1/5/2023Piper SandlerInitiated CoverageNeutral$75.00
12/23/2022BTIG ResearchBoost TargetBuy$62.00 ➝ $98.00
11/29/2022Morgan StanleyBoost TargetEqual Weight$73.00 ➝ $86.00
11/29/2022Leerink PartnersBoost TargetOutperform$65.00 ➝ $85.00
11/28/2022MizuhoReiterated RatingBuy$80.00
11/15/2022MizuhoBoost Target$80.00
11/11/2022GuggenheimBoost TargetBuy$72.00 ➝ $80.00
11/9/2022MizuhoBoost TargetBuy$76.00 ➝ $80.00
11/8/2022Morgan StanleyLower TargetEqual Weight$74.00 ➝ $73.00
11/8/2022Cantor FitzgeraldBoost Target$88.00 ➝ $96.00
11/1/2022Loop CapitalInitiated CoverageBuy$95.00
10/14/2022Morgan StanleyBoost TargetEqual Weight$71.00 ➝ $74.00
10/14/2022GuggenheimBoost TargetBuy$64.00 ➝ $72.00
10/5/2022CowenLower Target$125.00
10/4/2022HC WainwrightReiterated RatingBuy$210.00
9/30/2022Morgan StanleyLower TargetEqual Weight$75.00 ➝ $71.00
9/30/2022Jefferies Financial GroupLower TargetBuy$92.00 ➝ $90.00
9/7/2022MizuhoBoost TargetBuy$49.00 ➝ $76.00
8/30/2022Morgan StanleyBoost TargetEqual Weight$55.00 ➝ $75.00
8/23/2022HC WainwrightBoost TargetBuy$180.00 ➝ $210.00
8/22/2022Leerink PartnersBoost Target$50.00 ➝ $75.00
8/19/2022Truist FinancialBoost Target$100.00 ➝ $150.00
8/10/2022Cantor FitzgeraldLower Target$64.00 ➝ $54.00
8/10/2022Morgan StanleyBoost TargetEqual Weight$54.00 ➝ $55.00
7/8/2022Morgan StanleyBoost TargetEqual Weight$27.00 ➝ $54.00
6/29/2022CowenBoost TargetOutperform$120.00 ➝ $130.00
6/29/2022CowenBoost TargetOutperform$120.00 ➝ $130.00
6/29/2022Cantor FitzgeraldBoost TargetOverweight$47.00 ➝ $64.00
5/3/2022MizuhoLower Target$51.00 ➝ $49.00
3/29/2022Jefferies Financial GroupBoost TargetBuy$71.00 ➝ $77.00
3/2/2022Leerink PartnersLower TargetOutperform$65.00 ➝ $50.00
11/18/2021MizuhoLower TargetBuy$55.00 ➝ $51.00
11/9/2021Cantor FitzgeraldReiterated RatingOverweight
11/9/2021Leerink PartnersLower TargetOutperform$75.00 ➝ $65.00
9/15/2021HC WainwrightReiterated RatingBuy$180.00
8/30/2021HC WainwrightReiterated RatingBuy$225.00 ➝ $180.00
8/27/2021William BlairReiterated RatingBuy
8/23/2021MizuhoReiterated RatingBuy$55.00
8/10/2021BTIG ResearchLower TargetBuy ➝ Buy$123.00 ➝ $55.00
8/10/2021Leerink PartnersLower TargetPositive ➝ Outperform$115.00 ➝ $75.00
8/10/2021Truist FinancialLower TargetBuy$200.00 ➝ $160.00
8/10/2021MizuhoLower TargetBuy$118.00 ➝ $55.00
8/10/2021Morgan StanleyDowngradeOverweight ➝ Equal Weight$105.00 ➝ $34.00
7/16/2021William BlairSet TargetBuy$56.77
6/10/2021Berenberg BankInitiated CoverageBuy$112.00
5/26/2021Morgan StanleyBoost TargetOverweight$104.00 ➝ $105.00
5/12/2021BTIG ResearchReiterated RatingBuy
4/27/2021HC WainwrightBoost TargetBuy$210.00 ➝ $225.00
3/2/2021MizuhoLower TargetBuy$120.00 ➝ $118.00
3/2/2021Morgan StanleyBoost TargetOverweight$101.00 ➝ $104.00
1/8/2021Jefferies Financial GroupInitiated CoverageBuy$129.00
12/31/2020UBS GroupReiterated RatingPositive
12/15/2020MizuhoInitiated CoverageBuy$120.00
12/3/2020Cantor FitzgeraldBoost TargetPositive ➝ Overweight$131.00 ➝ $161.00
11/9/2020Morgan StanleyLower TargetOverweight$102.00 ➝ $101.00
10/1/2020William BlairReiterated RatingBuy
9/29/2020Bank of AmericaInitiated CoverageUnderperform$66.00
9/10/2020Morgan StanleyInitiated CoverageOverweight$102.00
9/4/2020William BlairReiterated RatingBuy
8/21/2020William BlairReiterated RatingBuy
8/10/2020William BlairReiterated RatingBuy
8/6/2020HC WainwrightReiterated RatingBuy$210.00
7/14/2020HC WainwrightReiterated RatingBuy$210.00
6/30/2020HC WainwrightReiterated RatingBuy$210.00
(Data available from 5/2/2020 forward)

News Sentiment Rating

1.14 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 16 very positive mentions
  • 13 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
10/4/2024
  • 13 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/3/2024
  • 35 very positive mentions
  • 26 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/3/2024
  • 19 very positive mentions
  • 14 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
1/2/2025
  • 19 very positive mentions
  • 32 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/1/2025
  • 39 very positive mentions
  • 46 positive mentions
  • 7 negative mentions
  • 0 very negative mentions
Mentions as of
3/3/2025
  • 22 very positive mentions
  • 18 positive mentions
  • 4 negative mentions
  • 2 very negative mentions
Mentions as of
4/2/2025
  • 39 very positive mentions
  • 20 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
5/2/2025

Current Sentiment

  • 39 very positive mentions
  • 20 positive mentions
  • 2 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Axsome Therapeutics logo
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.
Read More

Today's Range

Now: $112.24
Low: $109.88
High: $113.30

50 Day Range

MA: $113.88
Low: $95.65
High: $129.17

52 Week Range

Now: $112.24
Low: $64.11
High: $139.13

Volume

423,982 shs

Average Volume

681,767 shs

Market Capitalization

$5.47 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.88

Frequently Asked Questions

What sell-side analysts currently cover shares of Axsome Therapeutics?

The following Wall Street analysts have issued reports on Axsome Therapeutics in the last year: Bank of America Co., Cantor Fitzgerald, Citigroup Inc., Deutsche Bank Aktiengesellschaft, HC Wainwright, Jefferies Financial Group Inc., Leerink Partners, Mizuho, Morgan Stanley, Needham & Company LLC, Robert W. Baird, Royal Bank of Canada, StockNews.com, Truist Financial Co., UBS Group AG, Wells Fargo & Company, and William Blair.
View the latest analyst ratings for AXSM.

What is the current price target for Axsome Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Axsome Therapeutics in the last year. Their average twelve-month price target is $169.87, suggesting a possible upside of 51.3%. Mizuho has the highest price target set, predicting AXSM will reach $216.00 in the next twelve months. UBS Group AG has the lowest price target set, forecasting a price of $105.00 for Axsome Therapeutics in the next year.
View the latest price targets for AXSM.

What is the current consensus analyst rating for Axsome Therapeutics?

Axsome Therapeutics currently has 16 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe AXSM will outperform the market and that investors should add to their positions of Axsome Therapeutics.
View the latest ratings for AXSM.

What other companies compete with Axsome Therapeutics?

Other companies that are similar to Axsome Therapeutics include Summit Therapeutics, Teva Pharmaceutical Industries, Intra-Cellular Therapies, Genmab A/S and Dr. Reddy's Laboratories. Learn More about companies similar to Axsome Therapeutics.

How do I contact Axsome Therapeutics' investor relations team?

Axsome Therapeutics' physical mailing address is 200 BROADWAY 3RD FLOOR, NEW YORK NY, 10038. The company's listed phone number is (212) 332-3241. The official website for Axsome Therapeutics is axsome.com. Learn More about contacing Axsome Therapeutics investor relations.